Importer of Controlled Substances Application: Biopharmaceutical Research Company, 45926-45927 [2023-15185]
Download as PDF
45926
Federal Register / Vol. 88, No. 136 / Tuesday, July 18, 2023 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1209
(Enforcement)]
Certain Movable Barrier Operator
Systems and Components Thereof;
Notice of Commission Decision Not To
Review an Initial Determination
Terminating the Enforcement
Proceeding Based on Settlement;
Termination of the Proceeding
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 26) of the presiding
Administrative Law Judge (‘‘ALJ’’)
terminating the enforcement proceeding
based on settlement. The enforcement
proceeding is terminated.
FOR FURTHER INFORMATION CONTACT:
Houda Morad, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–4716. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.
SUPPLEMENTARY INFORMATION: On August
10, 2020, the Commission instituted an
investigation under section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337 (‘‘section 337’’), based on a
complaint filed by Overhead Door
Corporation of Lewisville, Texas and
GMI Holdings Inc. of Mount Hope, Ohio
(collectively, ‘‘Overhead Door’’). See 85
FR 48264–65 (Aug. 10, 2020). The
complaint, as supplemented, alleged a
violation of section 337 based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain movable barrier operator systems
and components thereof by reason of
infringement of U.S. Patent Nos.
8,970,345 (‘‘the ’345 patent’’); 7,173,516
(‘‘the ’516 patent’’); 7,180,260 (‘‘the ’260
patent’’); 9,483,935 (‘‘the ’935 patent’’);
7,956,718 (‘‘the ’718 patent’’); and
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:16 Jul 17, 2023
Jkt 259001
8,410,895 (‘‘the ’895 patent’’). See id.
The notice of investigation named The
Chamberlain Group, Inc. (now, The
Chamberlain Group, LLC) of Oak Brook,
Illinois (‘‘Chamberlain’’) as the
respondent in this investigation. See id.
On February 10, 2021, the
Commission terminated the
investigation as to the ’516 patent based
on the withdrawal of the allegations in
the complaint as to that patent. See
Order No. 10 (Jan. 19, 2021), unreviewed
by Comm’n Notice (Feb. 10, 2021).
On February 9, 2022, the Commission
issued a final determination finding a
violation of section 337, based on
Chamberlain’s infringement of the
asserted claims of the ’935, ’718, and
’895 patents, but not the ’345 and ’260
patents. See 87 FR 8605–06 (Feb. 15,
2022). The Commission further
determined to: (1) issue a limited
exclusion order against Chamberlain’s
infringing products and a cease and
desist order against Chamberlain
(collectively, the ‘‘remedial orders’’);
and (2) set a bond during the period of
Presidential review in the amount of
one hundred (100) percent of the
entered value of the infringing articles.
See id. On March 30, 2022, the
Commission issued modified remedial
orders to confirm that the covered
products or articles in the remedial
orders include garage door openers, gate
operators, and commercial operators.
See 87 FR 19709–10 (Apr. 5, 2022).
On April 11 and 12, 2022,
respectively, Overhead Door and
Chamberlain filed appeals from the
Commission’s final determination with
the U.S. Court of Appeals for the
Federal Circuit. See Chamberlain Grp.,
LLC v. ITC, Appeals Nos. 22–1664, 22–
1656 (consolidated).
On August 5, 2022, the Commission
instituted an enforcement proceeding
under Commission Rule 210.75 (19 CFR
210.75) to investigate alleged violations
of the remedial orders by Chamberlain’s
legacy and redesigned products. See 87
FR 48039 (Aug. 5, 2022). In addition to
Overhead Door and Chamberlain
(collectively, ‘‘the Private Parties’’), the
Office of Unfair Import Investigations
(‘‘OUII’’) was also named as a party to
the enforcement proceeding. See id.
On December 21, 2022, the
Commission terminated the
enforcement proceeding as to the ’718
patent based on withdrawal of the
enforcement complaint as to that patent.
See Order No. 14 (Dec. 1, 2022),
unreviewed by Comm’n Notice (Dec. 21,
2022).
On June 13, 2023, the parties filed a
joint stipulation of voluntary dismissal
of the appeals. On June 14, 2023, the
Federal Circuit dismissed the appeals.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
See Chamberlain Grp., LLC v. ITC,
Order, Appeal No. 22–1664, ECF No. 95
(Fed. Cir. June 14, 2023).
On June 13, 2023, the Private Parties
jointly moved to terminate the
enforcement proceeding based on
settlement. The joint motion states that
OUII supports the motion.
On June 14, 2023, the ALJ issued the
subject ID (Order No. 26) granting the
joint motion to terminate the
enforcement proceeding based on
settlement. The ID finds that the joint
motion complies with Commission Rule
210.21(b)(1), 19 CFR 210.21(b)(1). See ID
at 2–3. Specifically, the ID notes that the
joint motion includes confidential and
public copies of the settlement
agreement. See id. at 2. In addition, the
motion states that ‘‘there are no other
agreements, written or oral, express or
implied, between the Private Parties
concerning the subject matter of this
proceeding.’’ See id. Furthermore, in
accordance with Commission Rule
210.50(b)(2), 19 CFR 210.50(b)(2), the ID
finds ‘‘no evidence that terminating this
proceeding on the basis of settlement
would adversely affect’’ the public
interest. See id. at 3.
No petition for review of the subject
ID was filed.
The Commission has determined not
to review the subject ID. The
enforcement proceeding is terminated.
The Commission’s vote on this
determination took place on July 12,
2023.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: July 12, 2023.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2023–15119 Filed 7–17–23; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1224]
Importer of Controlled Substances
Application: Biopharmaceutical
Research Company
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Biopharmaceutical Research
Company has applied to be registered as
SUMMARY:
E:\FR\FM\18JYN1.SGM
18JYN1
45927
Federal Register / Vol. 88, No. 136 / Tuesday, July 18, 2023 / Notices
an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before August 17, 2023. Such
persons may also file a written request
for a hearing on the application on or
before August 17, 2023.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
ADDRESSES:
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on April 28, 2023,
Biopharmaceutical Research Company
11045 Commercial Parkway Castroville,
California 95012–3209, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Marihuana Extract ....................................................................................................................................................
Marihuana ................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................
The company plans to import
Marihuana Extract (7350), Marihuana
(7360) and Tetrahydrocannabinols
(7370) as flowering plants and cannabis
derivatives to support analytical
chemistry analyses, research and the
manufacturing of dosage forms for preclinical and clinical trials. No other
activity for this drug code is authorized
for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023–15185 Filed 7–17–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
ddrumheller on DSK120RN23PROD with NOTICES1
[OMB Number 1123–0014]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Application
for Certificates of Pardon for the
Offense of Simple Possession of
Marijuana
Office of the Pardon Attorney,
Department of Justice.
ACTION: 30-Day notice.
AGENCY:
The Office of the Pardon
Attorney, Department of Justice (DOJ),
SUMMARY:
VerDate Sep<11>2014
19:16 Jul 17, 2023
Jkt 259001
will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection was previously
published in the Federal Register on
May 9, 2023, allowing a 60-day
comment period.
DATES: The comment period for the
notice published on March 3, 2023, is
extended. Comments should be received
on or before August 15, 2023. August
17, 2023.
FOR FURTHER INFORMATION CONTACT: If
you have comments especially on the
estimated public burden or associated
response time, suggestions, or need a
copy of the proposed information
collection instrument with instructions
or additional information, please
contact: Kira Gillespie, Deputy Pardon
Attorney, Office of the Pardon Attorney,
950 Pennsylvania Avenue NW, Main
Justice—RFK Building, Washington, DC
20530; kira.gillespie@usdoj.gov; (202)
616–6073.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
7350
7360
7370
Schedule
I
I
I
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and/or
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Written comments and
recommendations for this information
collection should be submitted within
30 days of the publication of this notice
on the following website
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
30-day Review—Open for Public
Comments’’ or by using the search
function and entering either the title of
the information collection or the OMB
Control Number 1123–0014. This
information collection request may be
viewed at www.reginfo.gov. Follow the
instructions to view Department of
Justice, information collections
currently under review by OMB.
DOJ seeks PRA authorization for this
information collection for three (3)
years. OMB authorization for an ICR
cannot be for more than three (3) years
without renewal. The DOJ notes that
information collection requirements
E:\FR\FM\18JYN1.SGM
18JYN1
Agencies
[Federal Register Volume 88, Number 136 (Tuesday, July 18, 2023)]
[Notices]
[Pages 45926-45927]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15185]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1224]
Importer of Controlled Substances Application: Biopharmaceutical
Research Company
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Biopharmaceutical Research Company has applied to be
registered as
[[Page 45927]]
an importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
August 17, 2023. Such persons may also file a written request for a
hearing on the application on or before August 17, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on April 28, 2023, Biopharmaceutical Research Company
11045 Commercial Parkway Castroville, California 95012-3209, applied to
be registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana Extract....................... 7350 I
Marihuana............................... 7360 I
Tetrahydrocannabinols................... 7370 I
------------------------------------------------------------------------
The company plans to import Marihuana Extract (7350), Marihuana
(7360) and Tetrahydrocannabinols (7370) as flowering plants and
cannabis derivatives to support analytical chemistry analyses, research
and the manufacturing of dosage forms for pre-clinical and clinical
trials. No other activity for this drug code is authorized for this
registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023-15185 Filed 7-17-23; 8:45 am]
BILLING CODE P